Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * BEDU-ADDO FRANK	2. Issuer Name and Ticker or Trading Symbol PDS Biotechnology Corp [ PDSB ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President/CEO
(Last)          (First)          (Middle) C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 6/15/2021
(Street) FLORHAM PARK, NJ 07932 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	6/15/2021		M(1)		53174	A	$6.57	673681	D
Common Stock	6/15/2021		F(1)		27166	D	$12.86	646515	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.57	6/15/2021		M			53174	(2)	7/27/2021	Common Stock	53174	$0	0	D

Explanation of Responses:
(1)	On June 15, 2021, Mr. Bedu-Addo made a net exercise of 53,174 stock options, resulting in his acquisition of 26,008 common shares of the Issuer. The transaction was made pursuant to an exception to a lock-up agreement between Mr. Bedu Addo and Cantor Fitzgerald & Co.in connection with a public offering of common shares by the Issuer which closed on June 17, 2021.
(2)	The Stock Option is fully vested in accordance with its terms.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BEDU-ADDO FRANK C/O PDS BIOTECHNOLOGY CORPORATION 25B VREELAND ROAD FLORHAM PARK, NJ 07932	X		President/CEO

Signatures
/s/ Frank Bedu-Addo		6/17/2021
**Signature of Reporting Person		Date